First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Joly, Pascal; Maho-Vaillant, Maud; Prost-Squarcioni, Catherine; Hebert, Vivien; Houivet, Estelle; Calbo, Sébastien; Caillot, Frédérique; Golinski, Marie Laure; Labeille, Bruno; Picard-Dahan, Catherine; Paul, Carle; Richard, Marie-Aleth; Bouaziz, Jean David; Duvert-Lehembre, Sophie; Bernard, Philippe; Caux, Frederic; Alexandre, Marina; Ingen-Housz-Oro, Saskia; Vabres, Pierre; Delaporte, Emmanuel; Quereux, Gaelle; Dupuy, Alain; Debarbieux, Sebastien; Avenel-Audran, Martine; D'Incan, Michel; Bedane, Christophe; Bénéton, Nathalie; Jullien, Denis; Dupin, Nicolas; Misery, Laurent; Machet, Laurent; Beylot-Barry, Marie; Dereure, Olivier; Sassolas, Bruno; Vermeulin, Thomas; Benichou, Jacques; Musette, Philippe; French study group on autoimmune bullous skin diseases. Lancet (London, England). 2017; 389: p.2031-2040. doi:10.1016/S0140-6736(17)30070-3
Article